Semántica y sintaxis de los verbos de color en inglés antiguo

Este artículo propone un sistema de descomposición léxica para los verbos de color en inglés antiguo que recoge el significado central de este subdominio y explica el comportamiento morfosintáctico de sus miembros de acuerdo con los principios del Modelo Lexemático Funcional: estableciendo una plantilla léxica que reúne el conjunto de propiedades sintáctico-semánticas que caracterizan a este subdominio léxico; determinando el algoritmo de enlace entre la semántica y la sintaxis de estos predicados; y proponiendo reglas léxicas que justifican tanto las construcciones sintácticas en las éstos participan como la configuración morfológica de los argumentos que intervienen en esas construcciones.This paper presents a lexical analysis of the verbs of color in Old English that comprises information on the core meaning of this subdomain and the morphosyntactic behaviour of its members following the postulates of the Functional-Lexematic Model. In so doing, it establishes a lexical template with the whole of the syntactic and semantic features which characterise this subdomain; determines the linking algorithm between the semantics and the syntax of the predicates which form it; and proposes lexical rules illuminating both the syntactic patterns in which they appear and the morphology of the arguments which participate in those sequences as well

Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy

BACKGROUND AND OBJECTIVES: To study the clinical and laboratory features of antineurofascin-155 (NF155)-positive autoimmune nodopathy (AN). METHODS: Patients with anti-NF155 antibodies detected on routine immunologic testing were included. Clinical characteristics, treatment response, and functional scales (modified Rankin Scale [mRS] and Inflammatory Rasch-built Overall Disability Scale [I-RODS]) were retrospectively collected at baseline and at the follow-up. Autoantibody and neurofilament light (NfL) chain levels were analyzed at baseline and at the follow-up. RESULTS: Forty NF155+ patients with AN were included. Mean age at onset was 42.4 years. Patients presented with a progressive (75%), sensory motor (87.5%), and symmetric distal-predominant weakness in upper (97.2%) and lower extremities (94.5%), with tremor and ataxia (75%). Patients received a median of 3 (2-4) different treatments in 46 months of median follow-up. Response to IV immunoglobulin (86.8%) or steroids (72.2%) was poor in most patients, whereas 77.3% responded to rituximab. HLA-DRB1*15 was detected in 91.3% of patients. IgG4 anti-NF155 antibodies were predominant in all patients; anti-NF155 titers correlated with mRS within the same patient (r = 0.41, p = 0.004). Serum NfL (sNfL) levels were higher in anti-NF155+ AN than in healthy controls (36.47 vs 7.56 pg/mL, p < 0.001) and correlated with anti-NF155 titers (r = 0.43, p = 0.001), with I-RODS at baseline (r = -0.88, p < 0.001) and with maximum I-RODS achieved (r = -0.58, p = 0.01). Anti-NF155 titers and sNfL levels decreased in all rituximab-treated patients. DISCUSSION: Anti-NF155 AN presents a distinct clinical profile and good response to rituximab. Autoantibody titers and sNfL are useful to monitor disease status in these patients. The use of untagged-NF155 plasmids minimizes the detection of false anti-NF155+ cases. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that anti-NF155 antibodies associate with a specific phenotype and response to rituximab